Expert Panel Unanimously Decides Biogen's (BIIB) Aduhelm Offers no Patient Benefit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/6/2026
- Dow closes at record on Mideast optimism; SpaceX, AMD drag Nasdaq
- SpaceX tumbles amid AI spending concerns; Musk outlines $1 trillion revenue target
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
- New report warns China transceiver ban would hurt U.S. AI giants
- Salesforce president Srini Tallapragada steps down, becomes advisor
- Sandisk (SNDK) Tops Q4 EPS by $4.66, Offers Guidance
- EverCommerce names Alex Goor as new CEO, founder steps down
- Crude Inventory Rose 2.5 Million Barrels Last Week - EIA
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
Biogen (BIIB) PT Lowered to $400 at BofA Securities
July 16, 2021 8:25 AM EDTBofA Securities analyst Geoff Meacham lowered the price target on Biogen (NASDAQ: BIIB) to $400.00 (from $415.00) while maintaining a Neutral rating on commercial headwinds.
... MoreBiogen Alzheimer's drug hits roadblocks with some hospitals, insurers
July 15, 2021 3:03 PM EDTBy Deena Beasley
(Reuters) -Biogen Inc's Alzheimer's drug, the first new treatment for the memory-robbing disease in nearly 20 years, hit new barriers on Thursday with some large hospitals declining to use it and health insurers delaying a decision while awaiting coverage terms from Medicare.
An influential panel of medical experts also voted unanimously that there is no evidence that the drug, Aduhelm, provides a net health benefit to patients.
The 15-0 vote, at a meeting convened by the Institute of Clinical and Economic Review (ICER), followed confirmation from the Cleveland Clinic, one of the countrys... More
UnitedHealth says needs more information to decide on coverage policy for Biogen's Alzheimer's drug - CEO
July 15, 2021 9:44 AM EDTNEW YORK (Reuters) - UnitedHealth Group Inc said on Thursday that it is still developing its coverage policy for Biogen Inc.'s Alzheimer's drug Aduhelm, which was recently approved by the U.S. regulator.
UnitedHealth said it is awaiting guidance on coverage from the Centers for Medicare and Medicaid... More
UnitedHealth (UNH) Looking for Medicare Guidance on Aduhelm Coverage, Still Developing Policy on Biogen (BIIB) Alzheimer's Drug - Bloomberg
July 15, 2021 9:30 AM EDTUnitedHealth (NYSE: UNH) Looking for Medicare Guidance on Aduhelm Coverage, Still Developing Policy on Biogen (NASDAQ: BIIB) Alzheimer's Drug - Bloomberg
... MoreCleveland Clinic Bans Biogen's (BIIB) Aduhelm, Will Others Follow Suit?
July 15, 2021 8:02 AM EDTOn July 14th, 2021, the New York Times reported that 2 Ohio medical centers decided against administering Biogens (NASDAQ: BIIB) controversial Alzheimers drug Aduhelm to its patients.
The statement by the Cleveland Clinic, one of nations largest and most respectable medical centers reads: Based on the... More
What to Expect of Biogen's (BIIB) Aduhelm Review by Centers For Medicare and Medicaid Services
July 13, 2021 9:43 AM EDTOn July 12th, 2021, the US Centers for Medicare & Medicaid Services (CMS) announced the commencement of a National Coverage Determination (NCD) analysis of Biogen Incs (NASDAQ: BIIB) controversial Alzheimers drug Aduhelm.
The NCD review is expected to take between six and nine months and will determine the drugs eligibility for national coverage under the Medicare Advantage program, as well as any additional coverage restrictions under government-sponsored programs.
The process includes the... More
